Codinach Margarita, Blanco Margarita, Ortega Isabel, Lloret Mireia, Reales Laura, Coca Maria Isabel, Torrents Sílvia, Doral Manel, Oliver-Vila Irene, Requena-Montero Miriam, Vives Joaquim, Garcia-López Joan
Divisió de Teràpies Avançades/XCELIA, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat, Barcelona, Spain.
Divisió de Teràpies Avançades/XCELIA, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat, Barcelona, Spain.
Cytotherapy. 2016 Sep;18(9):1197-208. doi: 10.1016/j.jcyt.2016.05.012. Epub 2016 Jul 14.
Multipotent mesenchymal stromal cells (MSC) have achieved a notable prominence in the field of regenerative medicine, despite the lack of common standards in the production processes and suitable quality controls compatible with Good Manufacturing Practice (GMP). Herein we describe the design of a bioprocess for bone marrow (BM)-derived MSC isolation and expansion, its validation and production of 48 consecutive batches for clinical use.
BM samples were collected from the iliac crest of patients for autologous therapy. Manufacturing procedures included: (i) isolation of nucleated cells (NC) by automated density-gradient centrifugation and plating; (ii) trypsinization and expansion of secondary cultures; and (iii) harvest and formulation of a suspension containing 40 ± 10 × 10(6) viable cells. Quality controls were defined as: (i) cell count and viability assessment; (ii) immunophenotype; and (iii) sterility tests, Mycoplasma detection, endotoxin test and Gram staining.
A 3-week manufacturing bioprocess was first designed and then validated in 3 consecutive mock productions, prior to producing 48 batches of BM-MSC for clinical use. Validation included the assessment of MSC identity and genetic stability. Regarding production, 139.0 ± 17.8 mL of BM containing 2.53 ± 0.92 × 10(9) viable NC were used as starting material, yielding 38.8 ± 5.3 × 10(6) viable cells in the final product. Surface antigen expression was consistent with the expected phenotype for MSC, displaying high levels of CD73, CD90 and CD105, lack of expression of CD31 and CD45 and low levels of HLA-DR. Tests for sterility, Mycoplasma, Gram staining and endotoxin had negative results in all cases.
Herein we demonstrated the establishment of a feasible, consistent and reproducible bioprocess for the production of safe BM-derived MSC for clinical use.
尽管在生产过程中缺乏通用标准以及与药品生产质量管理规范(GMP)兼容的合适质量控制措施,但多能间充质基质细胞(MSC)在再生医学领域已占据显著地位。在此,我们描述了一种用于分离和扩增源自骨髓(BM)的MSC的生物工艺设计、其验证过程以及连续生产48批用于临床的产品。
从患者髂嵴采集BM样本用于自体治疗。生产程序包括:(i)通过自动密度梯度离心和接种分离有核细胞(NC);(ii)胰蛋白酶消化和传代培养的扩增;(iii)收获并配制含有40±10×10⁶个活细胞的悬液。质量控制定义为:(i)细胞计数和活力评估;(ii)免疫表型;(iii)无菌测试、支原体检测、内毒素测试和革兰氏染色。
首先设计了一个为期3周的生产生物工艺,然后在连续3次模拟生产中进行验证,之后生产48批用于临床的BM-MSC。验证包括对MSC身份和遗传稳定性的评估。关于生产,使用139.0±17.8 mL含有2.53±0.92×10⁹个活NC的BM作为起始材料,最终产品中获得38.8±5.3×10⁶个活细胞。表面抗原表达与MSC的预期表型一致,显示高水平的CD73、CD90和CD105,不表达CD31和CD45且低水平表达HLA-DR。所有情况下的无菌、支原体、革兰氏染色和内毒素测试结果均为阴性。
在此我们证明了建立一种可行、一致且可重复的生物工艺以生产用于临床的安全的源自BM的MSC。